Zydus Lifesciences Limited (BOM:532321)

Market Cap	987.17B
Revenue (ttm)	236.08B
Net Income (ttm)	45.72B
Shares Out	n/a
EPS (ttm)	45.44
PE Ratio	21.59
Forward PE	22.29
Dividend	11.00 (1.11%)
Ex-Dividend Date	Jul 25, 2025

Volume	17,101
Average Volume	60,525
Open	978.55
Previous Close	976.90
Day's Range	969.30 - 988.20
52-Week Range	797.05 - 1,159.00
Beta	n/a
RSI	51.17
Earnings Date	Aug 8, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.